Secondary progressive multiple sclerosis (SPMS) is diagnosed retrospectively and involves a clinical course characterized by a progressive accumulation of neurological disability, independent of relapses, following an initial relapsing–remitting (RR) phase. Our incomplete understanding of the pathological mechanisms underlying neurodegeneration in multiple sclerosis (MS) may explain why, to date, there is no definitive imaging or laboratory test that is able to inform us when the disease is clearly entering into a progressive phase and why the vast majority of clinical trials testing immunosuppressant and immunomodulating drugs in SPMS patients has so far yielded disappointing or mixed results. Here we discuss the definition(s) of SPMS and how it may vary, outcome measurements (current and emerging) and modern trial design.
Plantone, D., De Angelis, F., Doshi, A., & Chataway, J. (2016). Secondary Progressive Multiple Sclerosis: Definition and Measurement. CNS DRUGS, 30, 517-526 [10.1007/s40263-016-0340-9].
|Titolo:||Secondary Progressive Multiple Sclerosis: Definition and Measurement|
PLANTONE, DOMENICO (Corresponding)
|Citazione:||Plantone, D., De Angelis, F., Doshi, A., & Chataway, J. (2016). Secondary Progressive Multiple Sclerosis: Definition and Measurement. CNS DRUGS, 30, 517-526 [10.1007/s40263-016-0340-9].|
|Appare nelle tipologie:||1.1 Articolo in rivista|
File in questo prodotto:
|Secondary Progressive Multiple Sclerosis: Definition and Measurement.pdf||PDF editoriale||Open Access Visualizza/Apri|